ImmunOs Gets Cash Injection To Advance Potential First-In-Class Cancer Agent

Swiss Biotech Banks $74m

It has proved tricky of late for European biotechs to raise funds, but Switzerland's ImmunOs has gathered a group of top-tier US and European investors to help push lead asset IOS-1002, a first-in-class, multi-functional agent based on a naturally occurring human leukocyte antigen, towards the clinic.

US dollars
The funds will go towards development of ImmunOs’s lead program, IOS-1002 through Phase II trials. • Source: Archive

As new treatments go under the spotlight at the American Society of Clinical Oncology meeting in Chicago, ImmunOs Therapeutics AG has concluded a healthy financing round to help advance its new class of biologics for cancer which it hopes will soon feature at the world's largest oncology conference.

The Swiss biotech has announced the closing of an oversubscribed series B financing round totalling $74m, led by new investors Samsara Biocapital, Lightspeed Venture Partners and Gimv. The fundraising sees...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business

Finance Watch: Public Company Fundraising Sank Across The Board In Q1

 
• By 

Public Company Edition: Biomedtracker’s first quarter 2025 financing report shows follow-on offerings, IPOs and PIPEs fell sharply from Q1 of 2024. In recent transactions, Teva sold $2.3bn worth of notes, Regenxbio executed a royalty deal for up to $250m and Aura’s FOPO grossed $75m.

Deal Watch: QurAlis Targets Fragile-X Syndrome In Deals With Quiver, UMass

 
• By 

Plus the end of Sanofi’s six-target alliance with IGM, OmniAb’s deals with Veraxa and Angelini, alliances involving Skye/Arecor, Genprex/UTHealth Houston and more.

GSK’s Nucala Set For Dupixent Face-Off After FDA COPD Nod

 
• By 

The UK major's asthma drug gets a key expanded approval.

Zydus To Continue Mirabegron Sales, Looks To World-First Dual Shigella-Typhoid Vaccine

 
• By 

Zydus expects strong mirabegron sales in FY26 amid US litigation even as it builds a growth pillar in vaccines with a world-first, Gates Foundation-aided dual shigella-typhoid vaccine under development and others on the WHO prequalified list

More from Scrip

Merus Bispecific Impresses In Head And Neck Cancer

 

Updated Phase II results from petosemtamab have impressed ahead of ASCO, outshining Keytruda monotherapy and its bispecific rival from Bicara.

Zydus To Continue Mirabegron Sales, Looks To World-First Dual Shigella-Typhoid Vaccine

 
• By 

Zydus expects strong mirabegron sales in FY26 amid US litigation even as it builds a growth pillar in vaccines with a world-first, Gates Foundation-aided dual shigella-typhoid vaccine under development and others on the WHO prequalified list

Challenging Environment For Biopharma Is A Tailwind For Royalty Pharma

 

The royalty revenue stream acquirer has around 40 products in its portfolio and expects to generate roughly $3bn this year. Head of R&D and investments Marshall Urist talked about the investment strategy at the RBC Healthcare Conference.